NASDAQ:SKYE Skye Bioscience 5/10/2024 Earnings Report $1.73 +0.01 (+0.58%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 10/10/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Skye Bioscience EPS ResultsActual EPS-$0.18Consensus EPS -$0.16Beat/MissMissed by -$0.02One Year Ago EPSN/ASkye Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASkye Bioscience Announcement DetailsQuarterDate5/10/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Skye Bioscience Earnings HeadlinesSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Average Rating of "Moderate Buy" from BrokeragesOctober 11 at 3:01 AM | americanbankingnews.comFY2026 EPS Estimate for Skye Bioscience Lifted by AnalystOctober 11 at 2:12 AM | americanbankingnews.comAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.October 11 at 2:00 AM | Porter & Company (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Skye Bioscience, Inc. - SKYEOctober 8 at 5:45 PM | prnewswire.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Cantor FitzgeraldOctober 8 at 2:51 AM | americanbankingnews.comSkye Bioscience (NASDAQ:SKYE) Stock Rating Lowered by Craig HallumOctober 8 at 2:17 AM | americanbankingnews.comSee More Skye Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Skye Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skye Bioscience and other key companies, straight to your email. Email Address About Skye BioscienceSkye Bioscience (NASDAQ:SKYE) is a clinical-stage biotechnology company focused on the development of novel, selective cannabinoid type 1 (CB1) receptor modulators for the treatment of ocular diseases. Headquartered in Sunnyvale, California, Skye Bioscience leverages proprietary chemistry and formulation expertise to design and optimize compounds with high potency, tissue selectivity and favorable drug-like properties. The company’s lead product candidate is being evaluated for the treatment of glaucoma and other ophthalmic conditions characterized by elevated intraocular pressure. Skye Bioscience’s pipeline centers on synthetic cannabinoids engineered to avoid central nervous system side effects commonly associated with traditional cannabinoid therapies. By targeting CB1 receptors in ocular tissues, the company aims to deliver localized efficacy while minimizing systemic exposure. Preclinical studies have demonstrated promising pharmacokinetic and pharmacodynamic profiles, supporting the potential for twice-daily topical administration and rapid onset of action. Founded in 2018, Skye Bioscience has assembled a multidisciplinary leadership team with expertise in pharmacology, medicinal chemistry and ophthalmology. The company collaborates with contract research organizations and academic partners to advance its clinical programs through regulatory milestones and into human trials. As a Nasdaq-listed entity under the symbol SKYE, Skye Bioscience is positioning itself at the forefront of cannabinoid-derived therapeutics for eye health.View Skye Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Tesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 Earnings Upcoming Earnings Fastenal (10/13/2025)America Movil (10/14/2025)Wells Fargo & Company (10/14/2025)Citigroup (10/14/2025)Johnson & Johnson (10/14/2025)JPMorgan Chase & Co. (10/14/2025)The Goldman Sachs Group (10/14/2025)BlackRock (10/14/2025)ASML (10/15/2025)Kinder Morgan (10/15/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
